Quoin Pharma reports Q4/FY2023 net loss $8.7M; cash runway to H2 2025; positive QRX003 data

Quoin Pharmaceuticals, Ltd.

Net loss Q4 2023 $2.0M (flat YoY); FY2023 $8.7M vs $9.4M in 2022.
Cash & equivalents $10.7M as of Dec 31, 2023; plus $6.5M March 5 offering and $8M ELOC (pending shareholder approval).
Positive initial data from first 6 evaluable subjects: 5/6 had negligible/absent itch; all 6 showed skin score improvement.
No safety concerns reported in either ongoing Netherton Syndrome study; enrollment age lowered to 14+.
Expects cash runway to extend into H2 2025.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Quoin Pharmaceuticals, Ltd. reported the quarter and year ended December 31, 2023 results: net income Net loss for the quarter ended December 31, 2023 was approximately $2.0 million compared to approximately $2.0 million f.

Period: the quarter and year ended December 31, 2023
Net income: Net loss for the quarter ended December 31, 2023 was approximately $2.0 million compared to approximately $2.0 million f
Result: reported results

Exact text from the filing

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today provides a business update and announces financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Quoin Pharmaceuticals, Ltd. filing history →

Source: SEC EDGAR

accession 0001104659-24-033990

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.